ACHC · Acadia Healthcare Company, Inc. · Stock research

Current Thesis

The behavioral-health turnaround that began printing in Q1 has gone from a single analyst's call to a full sell-side re-rate, and the tape has followed: ACHC trades near $34.50 (2026-07-26), a fresh 52-week high above the prior $30.20 ceiling. In eleven days four desks lifted targets in unison — UBS to $39 (2026-07-09), Keybanc to $40 and TD Cowen to $36 (both 2026-07-14), Guggenheim to $38 (2026-07-20) — every one above the old high, underwriting the raised FY26 guide and the Florida Directed Payment Program upside rather than the bounce off the $11.43 low. Returning CEO Debra Osteen's operating reset is the story the Street is buying. The catch is timing: Q2 lands after the close on 2026-07-28 (call 2026-07-29), two sessions out, and it is the whole thesis test — Florida DPP is the line that either extends the breakout or fails it. With ~29% of the float short and the stock already up ~40% since early June, the narrative is accelerating but stretched into a binary event still shadowed by an open DOJ/SEC probe. A fresh entry the day before the print is chasing extension into an event; the cleaner engagement is the post-print reaction.

Bullish and bearish views on Acadia Healthcare Company, Inc.

The model's bull view on Acadia Healthcare Company, Inc. (ACHC), in brief: Sell-side cluster above the old high: UBS $39 (2026-07-09), Keybanc $40 and TD Cowen $36 (2026-07-14), Guggenheim $38 (2026-07-20) — four raises in eleven days, all above the $30.20 52-week high, with the leading band now $36–40 versus a lagging $29 consensus average that has… The bear view: DOJ + SEC probe still open: unresolved per the 2025 annual report; a DOJ grand-jury subpoena (disclosed 2024) and an SEC inquiry remain live, with $135M of legal fees run through 2025. Both cases follow in full.

Bull Case

• Sell-side cluster above the old high: UBS $39 (2026-07-09), Keybanc $40 and TD Cowen $36 (2026-07-14), Guggenheim $38 (2026-07-20) — four raises in eleven days, all above the $30.20 52-week high, with the leading band now $36–40 versus a lagging $29 consensus average that has yet to catch up.
• Clean Q1 + raised FY26 guide (2026-04-29): revenue $828.8M (+7.6% YoY); same-facility revenue +7.3% (1.6% more patient days, 5.6% higher revenue/day); acute inpatient psych $470.7M (+14% YoY). FY26 guide lifted to revenue $3.37–3.45B / adj. EBITDA $580–615M / adj. EPS $1.35–1.60.
• Concrete Q2 bar: management guided Q2 to revenue $835–850M / adj. EBITDA $142–152M / adj. EPS $0.30–0.40 — the measurable line the 2026-07-28 print is judged against, with Florida DPP the swing factor flagged as a further guide-raise trigger.
• ~29% short interest into a confirmed guide raise: a heavily short float turns any Q2 beat or DPP approval into forced covering on top of fundamental buying.
• Capacity + cash inflection: 275 facilities / ~12,400 beds across 40 states + Puerto Rico (2026-03-31), ~84,000 patients daily; 400–600 net new beds planned in 2026 while cutting capex $300M+ versus 2025, with two JV beds opening in Q2 (144-bed Orlando Health; 96-bed Methodist Jennie Edmundson, Iowa).
• Management credibility: the re-rate is anchored to returning CEO Debra Osteen, the operator the Street associates with Acadia's prior growth run.

Bear Case

• DOJ + SEC probe still open: unresolved per the 2025 annual report; a DOJ grand-jury subpoena (disclosed 2024) and an SEC inquiry remain live, with $135M of legal fees run through 2025. A charging decision or consent decree is a single-session -20%+ tail no guide raise offsets. The closed 2024 ~$20M Medicare settlement and a separate ~$179M investor securities settlement did not resolve it.
• $105M jury verdict (2026-05-12): subsidiary Fashion Valley CTC hit with $35M compensatory + $70M punitive in a retaliatory-termination case; management is pursuing post-trial motions and appeal but concedes no assurance damages shrink.
• Extended into a binary: ~$34.50 is roughly +40% off the early-June ~$24.48 and near 3x the $11.43 low, above the $29 consensus average and pressing the lower bound of the $36–40 leading targets. Most of the re-rate is priced; further upside now depends on the print itself.
• The whole thesis is one line: if Florida DPP doesn't show and Q2 guidance holds flat, the breakout above $30.20 becomes a bull trap, and a heavily short, extended name gaps the other way.
• Consensus is split: 8 Buy / 6 Hold / 1 Sell — the enthusiasm is real but not unanimous, and the Holds anchor to the legal overhang the bulls are discounting.

Setup & Price Structure

• Breakout confirmed, extended: after digesting the mid-$20s through June (June high ~$26.84, fade to $23.50 on 2026-06-17), the mid-July upgrade wave carried ACHC through the $30.20 52-week high to ~$34.50 (2026-07-26) — a clean move to new highs running well above its rising moving averages after a ~40% seven-week advance.
• Support ladder: first retest is the prior $30.20 high (now would-be support); below that the June recovery base near $22.66; the $11.43 low is the distant floor.
• Resistance / targets: the leading PT band $36–40 sits just overhead; with no prior price history above $30.20, the tape is in discovery.
• Squeeze mechanics: ~29% short interest is the accelerant — constructive on a beat, but it cuts both ways if the print disappoints and shorts press a failed breakout.
• Trap read: the narrative is accelerating and cluster-confirmed, yet the entry sits two sessions before a binary print, at new highs, above the average target — buying here is chasing extension into an event, not stepping onto a base. The disciplined stance is to let the print clear and engage the reaction.

Catalyst Calendar (next 30 days)

• Rolling: further sell-side revisions likely in the 48 hours after the print as desks mark to the DPP number; DOJ/SEC probe headlines remain an unscheduled tail through the window.

Elapsed catalysts

• 2026-07-28 (after close): Q2 2026 earnings release — the binary. Bar is revenue $835–850M / adj. EBITDA $142–152M / adj. EPS $0.30–0.40; Florida DPP contribution and any FY26 guide revision are the watched lines. Three-trading-day pre-print blackout applies. (passed 12d ago)
• 2026-07-29, 9:00 a.m. ET: Q2 earnings conference call — DPP color, bed-additions cadence, and any legal-timeline commentary. (passed 11d ago)

What Would Change Our Mind

• Bull confirmation: a Q2 beat with an explicit Florida DPP contribution and a raised FY26 guide, holding the breakout with a weekly close above ~$34–35, validates the $36–40 targets and re-opens engagement on strength.
• Thesis break: a weekly close below $30 surrenders the breakout above the $30.20 prior high and turns the re-rate into a failed breakout; a close under the $22.66 June base confirms a full structure break.
• Discrete kill: a DOJ/SEC charging decision or consent-decree 8-K, or the $105M verdict upheld/expanded on appeal — either is a step-change in the legal tail independent of price.
• Guide failure: a Q2 print holding FY26 guidance flat despite DPP removes the reason the sell-side cluster moved above the old high.

Correlation Notes

• Facility-based behavioral peers: moves with UHS and other psychiatric/facility operators on reimbursement and directed-payment-program headlines; the Florida DPP read-through is name-specific, but Medicaid supplemental-payment policy is a shared driver.
• Policy beta: Medicaid rate and DPP policy, plus any federal behavioral-health funding shift, drive the group more than broad market beta — a low-beta defensive-health name whose dominant risk is legal rather than macro.
• Short-squeeze cohort: the ~29% short interest ties near-term intraday behavior to squeeze dynamics more than to sector flows into the print.